| | Variables | Patients, no. (%) | | Favorable outcome (, 61.8%) | Poor outcome (, 38.2%) | value |
| | Demographic | | | | | Mean age, y (SD) | 58.6 (11.5) | 62.7 (12.4) | 0.011 | | Sex, male, (%) | 87 (60.4) | 61 (68.5) | 0.211 | | Medical history | | | | | Alcohol consumption, (%) | 57 (39.6) | 38 (42.7) | 0.638 | | Smoking, (%) | 61 (42.4) | 44 (49.4) | 0.291 | | Hypertension, (%) | 103 (71.5) | 71 (79.8) | 0.160 | | Diabetes mellitus, (%) | 14 (9.7) | 12 (13.5) | 0.376 | | Clinical features | | | | | Systolic blood pressure, mmHg (SD) | 167.5 (26.0) | 176.6 (35.0) | 0.035 | | Diastolic blood pressure, mmHg (SD) | 97.3 (14.5) | 101.2 (21.6) | 0.128 | | Admission GCS score, median (IQR) | 14 (13-15) | 10 (7-14) | <0.001 | | Baseline ICH volume, mL (IQR) | 11.7 (7.1-16.4) | 18.7 (11.1-32.0) | <0.001 | | Time from onset to CT, h(IQR) | 2.0 (1.0-4.0) | 2.0 (1.0-3.0) | 0.046 | | Admission PHE volume, mL (IQR) | 5.3 (2.6-8.3) | 7.5 (4.7-14.7) | <0.001 | | Follow-up PHE volume, mL (IQR) | 7.8 (4.0-11.1) | 13.7 (7.0-25.1) | <0.001 | | Absolute PHE increase, mL (IQR) | 1.5 (0.1-3.5) | 3.8 (1.2-11.9) | <0.001 | | Early PHE expansion, (%) | 17 (11.8) | 39 (43.8) | <0.001 | | SAH at baseline CT, (%) | 11 (7.6) | 9 (10.1) | 0.513 | | IVH at baseline CT, (%) | 28 (19.4) | 47 (52.8) | <0.001 | | Hematoma growth, (%) | 27 (18.8) | 45 (50.6) | <0.001 | | ICH location | | | | | Basal ganglia hemorrhage, (%) | 95 (66.0) | 43 (48.3) | 0.008 | | Thalamic hemorrhage, (%) | 29 (20.1) | 33 (37.1) | 0.004 | | Other, (%) | 20 (13.9) | 13 (14.6) | 0.879 | | Outcome | | | | | In-hospital mortality, (%) | 0 (0) | 16 (18.0) | <0.001 | | 30-day mortality, (%) | 0 (0) | 33 (37.1) | <0.001 | | 90-day mRS, median (IQR) | 1 (0-2) | 6 (4.5-6) | <0.001 |
|
|
